Heart disease remains the leading cause of death in the world. One reason is that unlike other tissues, such as bone and skin, the heart has remarkably poor regenerative capability after an injury such as a heart attack. Scientists have therefore searched for heart cells that have regenerative properties. A new study by the Yoshinori
Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), announced today that its lentiviral based gene therapy, developed in collaboration with French and British teams, has demonstrated long-term efficacy in eight patients with Wiskott-Aldrich syndrome, a rare and severe immune deficiency. “These results confirm the stability and good
A new type of lightweight 3D-printed back brace capable of sensing how effectively it fits patients could lead to improved treatment for scoliosis, its developers say. Scoliosis, a common form of spine deformity, affects around three percent of the population, most often between the ages of 10 and 15. It can be corrected in younger
Cardiovascular care essential part of post-infection care An in-depth analysis of federal health data indicates that people who have had COVID-19 are at increased risk of developing cardiovascular complications within the first month to a year after infection. Such complications include disruptive heart rhythms, inflammation of the heart, blood clots, stroke, coronary artery disease, heart
A system developed by Grégoire Courtine and Jocelyne Bloch now enables patients with a complete spinal cord injury to stand, walk and even perform recreational activities like swimming, cycling andcanoeing. The images made headlines around the world in late 2018. David Mzee, who had been left paralyzed by a partial spinal cord injury suffered in
A novel gene therapy promoted transfusion independence in more than 90 percent of adult and pediatric patients with transfusion-dependent beta-thalassemia, according to a recent clinical trial published in The New England Journal of Medicine. The therapy represents a potentially curative treatment option for patients who must otherwise rely on life-long red blood cell transfusions. This approach provides
Two patients represent longest-known CAR T cell response to date, providing insight into treatment effects and outcomes In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first
